首页 > 最新文献

Journal of Breast Cancer最新文献

英文 中文
Somatic Mutations of TP53 Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study. 靶向下一代测序鉴定的TP53体细胞突变是原发性可手术乳腺癌的不良预后因素:一项单中心研究
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-10-01 DOI: 10.4048/jbc.2022.25.e41
Jung Ho Park, Mi Jung Kwon, Jinwon Seo, Ho Young Kim, Soo Kee Min, Lee Su Kim

Few studies have reported on the clinical utility of targeted next-generation sequencing (NGS) for breast cancer in Korea. We retrospectively reviewed the targeted NGS data of 219 patients with breast cancer who underwent surgical resection between August 2018 and April 2021. Here, we described the mutational profiles of breast cancer and examined their prognostic implications. The most frequently mutated gene was PIK3CA (n = 97/219, 44.3%), followed by TP53 (n = 79/219, 36.1%), AKT1 (n = 23/219, 10.5%), and GATA3 (n = 20/219, 9.1%). TP53 mutations were associated with aggressive histologic features. We followed up for 31 (range, 1-39) months and observed 11 (5.0%) recurrences: nine were TP53 mutant and two were TP53 wild-type. Multivariable analysis revealed that TP53 mutation was an independent prognostic factor for recurrence (p = 0.012). Although no drug is currently available for TP53 mutations, it is valuable to know the mutational status of TP53 for the precise management of breast cancer.

在韩国,靶向下一代测序(NGS)治疗乳腺癌的临床应用研究很少。我们回顾性回顾了2018年8月至2021年4月219例接受手术切除的乳腺癌患者的靶向NGS数据。在这里,我们描述了乳腺癌的突变概况,并检查了它们的预后意义。最常见的突变基因是PIK3CA (n = 97/219, 44.3%),其次是TP53 (n = 79/219, 36.1%)、AKT1 (n = 23/219, 10.5%)和GATA3 (n = 20/219, 9.1%)。TP53突变与侵袭性组织学特征相关。随访31个月(1-39个月),11例(5.0%)复发,其中9例为TP53突变型,2例为TP53野生型。多变量分析显示TP53突变是复发的独立预后因素(p = 0.012)。虽然目前还没有针对TP53突变的药物,但了解TP53的突变状态对于乳腺癌的精确治疗是有价值的。
{"title":"Somatic Mutations of <i>TP53</i> Identified by Targeted Next-Generation Sequencing Are Poor Prognostic Factors for Primary Operable Breast Cancer: A Single-Center Study.","authors":"Jung Ho Park,&nbsp;Mi Jung Kwon,&nbsp;Jinwon Seo,&nbsp;Ho Young Kim,&nbsp;Soo Kee Min,&nbsp;Lee Su Kim","doi":"10.4048/jbc.2022.25.e41","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e41","url":null,"abstract":"<p><p>Few studies have reported on the clinical utility of targeted next-generation sequencing (NGS) for breast cancer in Korea. We retrospectively reviewed the targeted NGS data of 219 patients with breast cancer who underwent surgical resection between August 2018 and April 2021. Here, we described the mutational profiles of breast cancer and examined their prognostic implications. The most frequently mutated gene was <i>PIK3CA</i> (n = 97/219, 44.3%), followed by <i>TP53</i> (n = 79/219, 36.1%), <i>AKT1</i> (n = 23/219, 10.5%), and <i>GATA3</i> (n = 20/219, 9.1%). <i>TP53</i> mutations were associated with aggressive histologic features. We followed up for 31 (range, 1-39) months and observed 11 (5.0%) recurrences: nine were <i>TP53</i> mutant and two were <i>TP53</i> wild-type. Multivariable analysis revealed that <i>TP53</i> mutation was an independent prognostic factor for recurrence (<i>p</i> = 0.012). Although no drug is currently available for <i>TP53</i> mutations, it is valuable to know the mutational status of <i>TP53</i> for the precise management of breast cancer.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 5","pages":"379-386"},"PeriodicalIF":2.4,"publicationDate":"2022-10-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/d3/f9/jbc-25-379.PMC9629967.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10448057","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 4
Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review. 新诊断乳腺癌患者的乳房磁共振成像:综述。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-08-01 DOI: 10.4048/jbc.2022.25.e35
Soo-Yeon Kim, Nariya Cho

Despite the high sensitivity and widespread use of preoperative magnetic resonance imaging (MRI), the American Cancer Society and the National Comprehensive Cancer Network guidelines do not recommend the routine use of preoperative MRI owing to the conflicting results and lack of clear benefit to the surgical outcome (reoperation and mastectomy) and long-term clinical outcomes (local recurrence and metachronous contralateral breast cancer). Preoperative MRI detects additional cancers that are occult at mammography and ultrasound but increases the rate of mastectomy. Concerns about overdiagnosis and overtreatment of preoperative MRI might be mitigated by adjusting the confounding factors when conducting studies, using the state-of-the-art image-guided biopsy technique, applying the radiologists' cumulative experiences in interpreting MRI findings, and performing multiple lumpectomies in patients with multicentric cancer. Among the various imaging methods, dynamic contrast-enhanced MRI has the highest accuracy in predicting pathologic complete response after neoadjuvant chemotherapy. Prospective trials aimed at applying the MRI information to the de-escalation of surgical or radiation treatments are underway. In this review, current studies on the clinical outcomes of preoperative breast MRI are updated, and circumstances in which MRI may be useful for surgical planning are discussed.

尽管术前磁共振成像(MRI)具有高灵敏度和广泛应用,但美国癌症协会和国家综合癌症网络指南不建议常规使用术前MRI,因为结果相互矛盾,对手术结果(再次手术和乳房切除术)和长期临床结果(局部复发和异时性对侧乳腺癌)缺乏明确的益处。术前MRI可以检测到其他在乳房x光检查和超声检查中未发现的癌症,但增加了乳房切除术的几率。对术前MRI过度诊断和过度治疗的担忧可以通过在进行研究时调整混杂因素,使用最先进的图像引导活检技术,应用放射科医生在解释MRI结果方面的累积经验,以及对多中心癌症患者进行多肿瘤切除术来缓解。在各种成像方法中,动态增强MRI预测新辅助化疗后病理完全缓解的准确性最高。旨在将MRI信息应用于外科或放射治疗降级的前瞻性试验正在进行中。在这篇综述中,更新了目前关于术前乳房MRI临床结果的研究,并讨论了MRI可能对手术计划有用的情况。
{"title":"Breast Magnetic Resonance Imaging for Patients With Newly Diagnosed Breast Cancer: A Review.","authors":"Soo-Yeon Kim,&nbsp;Nariya Cho","doi":"10.4048/jbc.2022.25.e35","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e35","url":null,"abstract":"<p><p>Despite the high sensitivity and widespread use of preoperative magnetic resonance imaging (MRI), the American Cancer Society and the National Comprehensive Cancer Network guidelines do not recommend the routine use of preoperative MRI owing to the conflicting results and lack of clear benefit to the surgical outcome (reoperation and mastectomy) and long-term clinical outcomes (local recurrence and metachronous contralateral breast cancer). Preoperative MRI detects additional cancers that are occult at mammography and ultrasound but increases the rate of mastectomy. Concerns about overdiagnosis and overtreatment of preoperative MRI might be mitigated by adjusting the confounding factors when conducting studies, using the state-of-the-art image-guided biopsy technique, applying the radiologists' cumulative experiences in interpreting MRI findings, and performing multiple lumpectomies in patients with multicentric cancer. Among the various imaging methods, dynamic contrast-enhanced MRI has the highest accuracy in predicting pathologic complete response after neoadjuvant chemotherapy. Prospective trials aimed at applying the MRI information to the de-escalation of surgical or radiation treatments are underway. In this review, current studies on the clinical outcomes of preoperative breast MRI are updated, and circumstances in which MRI may be useful for surgical planning are discussed.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 4","pages":"263-277"},"PeriodicalIF":2.4,"publicationDate":"2022-08-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/82/aa/jbc-25-263.PMC9411024.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"9547715","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Association Between Smoking Status and Breast Cancer Recurrence: A Systematic Review 吸烟状况与乳腺癌复发之间的关系:一项系统综述
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-05-20 DOI: 10.4048/jbc.2022.25.e23
Muna Alkhaifi, Adam Clayton, T. Kishibe, J. Simpson
Purpose To determine whether smoking status (active/passive) affects recurrence events after breast cancer (BC) diagnosis among women. Methods A comprehensive literature search of MEDLINE, Cochrane Central, EMBASE, and Web of Science databases on smoking status and BC outcomes retrieved 5,940 articles. After reviewing the inclusion and exclusion criteria, we selected 14 articles for a full review and synthesis. Results Five studies were cohort retrospective, 6 were case-control, 2 were prospective cohort studies, and 1 was a secondary analysis of a randomized control trial. Among the 8 articles that focused on active smoking, 6 showed an increased risk of BC recurrence, and 2 showed no evidence of such an association. Studies that examined former smokers found little evidence of an increased risk of BC recurrence. This association may be dose-dependent. Conclusion Given the current evidence, although limited, active smokers should quit smoking after BC diagnosis as trends indicate a positive association between active smoking and BC recurrence. More robust evidence is needed to assess such associations and examine the outcomes of quitting smoking in such patients.
目的确定吸烟状态(主动/被动)是否影响女性癌症(BC)诊断后的复发事件。方法综合检索MEDLINE、Cochrane Central、EMBASE和Web of Science数据库中关于吸烟状况和BC结果的文献,检索5940篇文章。在审查了纳入和排除标准后,我们选择了14篇文章进行全面审查和综合。结果5项研究为队列回顾性研究,6项为病例对照研究,2项为前瞻性队列研究,1项为随机对照试验的二次分析。在8篇关注主动吸烟的文章中,6篇文章显示BC复发的风险增加,2篇文章没有显示这种关联的证据。对前吸烟者进行的研究发现,几乎没有证据表明BC复发的风险增加。这种关联可能是剂量依赖性的。结论鉴于目前的证据,尽管有限,但积极吸烟者应在诊断为BC后戒烟,因为趋势表明积极吸烟与BC复发呈正相关。需要更有力的证据来评估这种关联,并检查这些患者戒烟的结果。
{"title":"The Association Between Smoking Status and Breast Cancer Recurrence: A Systematic Review","authors":"Muna Alkhaifi, Adam Clayton, T. Kishibe, J. Simpson","doi":"10.4048/jbc.2022.25.e23","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e23","url":null,"abstract":"Purpose To determine whether smoking status (active/passive) affects recurrence events after breast cancer (BC) diagnosis among women. Methods A comprehensive literature search of MEDLINE, Cochrane Central, EMBASE, and Web of Science databases on smoking status and BC outcomes retrieved 5,940 articles. After reviewing the inclusion and exclusion criteria, we selected 14 articles for a full review and synthesis. Results Five studies were cohort retrospective, 6 were case-control, 2 were prospective cohort studies, and 1 was a secondary analysis of a randomized control trial. Among the 8 articles that focused on active smoking, 6 showed an increased risk of BC recurrence, and 2 showed no evidence of such an association. Studies that examined former smokers found little evidence of an increased risk of BC recurrence. This association may be dose-dependent. Conclusion Given the current evidence, although limited, active smokers should quit smoking after BC diagnosis as trends indicate a positive association between active smoking and BC recurrence. More robust evidence is needed to assess such associations and examine the outcomes of quitting smoking in such patients.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"278 - 287"},"PeriodicalIF":2.4,"publicationDate":"2022-05-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"42005408","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Optimal Timing of Imaging Examinations in Patients With Newly Diagnosed Breast Cancer in the COVID-19 Pandemic Era COVID-19大流行时代新发乳腺癌患者影像学检查的最佳时机
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-05-17 DOI: 10.4048/jbc.2022.25.e22
J. Chang, S. Ha
Our study was a retrospective study of patients with newly diagnosed breast cancer, who received concurrent coronavirus disease 2019 (COVID-19) vaccination in the ipsilateral arm, and underwent biopsy or surgery for axillary lymph nodes between April 2021 and September 2021. In our study population, the median interval between the most recent vaccination and imaging assessment was 26 days (range, 4–49 days) [1]. Previous reports have indicated that lymphadenopathy can develop as early as one day after the first dose, and is most likely to be seen within 14 days. However, the time to resolution of COVID-19 vaccine-associated lymphadenopathy varies, with persistent axillary lymphadenopathy observed up to 43 weeks post-vaccination [3]. In addition, patient and vaccine factors such as younger age, first dose, and mRNA vaccine type induce a higher incidence of axillary lymphadenopathy [4].
我们的研究是对新诊断的癌症患者的回顾性研究,这些患者在2021年4月至2021年9月期间在同侧手臂同时接种了2019冠状病毒病(新冠肺炎)疫苗,并接受了腋窝淋巴结活组织检查或手术。在我们的研究人群中,最近一次疫苗接种和影像学评估之间的中位间隔为26天(范围为4-49天)[1]。先前的报告表明,淋巴结病最早可以在第一次给药后一天发生,最有可能在14天内出现。然而,新冠肺炎疫苗相关淋巴结病的解决时间各不相同,在疫苗接种后43周内观察到持续性腋窝淋巴结病[3]。此外,患者和疫苗因素,如年龄较小、第一剂和信使核糖核酸疫苗类型,会导致腋窝淋巴结病的发病率较高[4]。
{"title":"The Optimal Timing of Imaging Examinations in Patients With Newly Diagnosed Breast Cancer in the COVID-19 Pandemic Era","authors":"J. Chang, S. Ha","doi":"10.4048/jbc.2022.25.e22","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e22","url":null,"abstract":"Our study was a retrospective study of patients with newly diagnosed breast cancer, who received concurrent coronavirus disease 2019 (COVID-19) vaccination in the ipsilateral arm, and underwent biopsy or surgery for axillary lymph nodes between April 2021 and September 2021. In our study population, the median interval between the most recent vaccination and imaging assessment was 26 days (range, 4–49 days) [1]. Previous reports have indicated that lymphadenopathy can develop as early as one day after the first dose, and is most likely to be seen within 14 days. However, the time to resolution of COVID-19 vaccine-associated lymphadenopathy varies, with persistent axillary lymphadenopathy observed up to 43 weeks post-vaccination [3]. In addition, patient and vaccine factors such as younger age, first dose, and mRNA vaccine type induce a higher incidence of axillary lymphadenopathy [4].","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"260 - 261"},"PeriodicalIF":2.4,"publicationDate":"2022-05-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"47384219","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories 在泰国和主要亚洲地区获得乳腺癌系统治疗的差异
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-05-13 DOI: 10.4048/jbc.2022.25.e21
S. Ithimakin, N. Parinyanitikul, Sung-Bae Kim, Y. Yap, J. Tsang, I. Soong, Y. Ozaki, S. Ohno, M. Ono, Jack Junjie Chan, Hung-Chun Cheng, T. Dejthevaporn
Purpose Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the cancer mortality-to-incidence ratio, we compared access to BC drugs in Thailand with that in other Asian countries. Methods BC experts involved in the Breast International Group (BIG)-Asia in six representative groups for countries or special administrative region (SAR) in Asia (Hong Kong SAR, Japan, Korea, Taiwan, Thailand, and Singapore) were invited to participate in the survey. The questionnaire addressed national health reimbursement schemes, molecular testing for early BC (EBC), availability and accessibility of BC drugs. Accessibility and reimbursement of the drugs were reported based on their listing as essential medicines in the World Health Organization Model List of Essential Medicines (WHO-EML) and their nomination as effective drugs in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). The study was approved by all participating BIG-Asia organizations in November 2021. Results Genomic tests for EBC were non-reimbursable in all surveyed territories. Reimbursement and co-payment of BC drugs vary between and within these regions (particularly Thailand). Most drugs in the WHO-EML and ESMO-MCBS (A/B for EBC and 4/5 for advanced BC) were accessible in all surveyed territories. However, the accessibility of effective but costly WHO-EML and ESMO-MCBS drugs was not uniform in Thailand. There was an evident disparity for individuals covered by the Thai Social Security/Universal Health Coverage schemes. Conclusion Essential BC drugs are generally accessible in selected BIG-Asia countries or SAR. There is a disparity in accessing high-cost drugs in Thailand compared with other Asian territories.
乳腺癌(BC)的治疗已经从化疗转向靶向治疗。一些靶向药物已经证明了生存率的提高。鉴于国家医疗资源与癌症死亡率-发病率相关,我们比较了泰国与其他亚洲国家BC药物的可及性。方法邀请乳腺国际组织(BIG)亚洲6个亚洲国家或特别行政区(香港特别行政区、日本、韩国、台湾、泰国和新加坡)代表小组的BC专家参与调查。调查问卷涉及国家医疗报销计划、早期不列颠哥伦比亚省(EBC)分子检测、不列颠哥伦比亚省药物的可得性和可及性。这些药物的可及性和报销情况是根据它们在世界卫生组织基本药物标准清单(WHO-EML)中被列为基本药物,以及它们在欧洲肿瘤医学学会临床效益等级量表(ESMO-MCBS)中被提名为有效药物进行报告的。该研究于2021年11月获得BIG-Asia所有参与组织的批准。结果在所有调查地区,EBC基因组检测都是不可报销的。这些地区(特别是泰国)之间和内部BC药物的报销和共同支付有所不同。在所有调查地区,WHO-EML和ESMO-MCBS (EBC为A/B,晚期BC为4/5)中的大多数药物均可获得。然而,有效但昂贵的WHO-EML和ESMO-MCBS药物在泰国的可及性并不统一。泰国社会保障/全民健康保险计划所涵盖的个人之间存在明显的差异。结论在部分大亚洲国家或特别行政区,基本BC药物基本可及性较好。泰国在高成本药物可及性方面与亚洲其他地区存在差异。
{"title":"Disparities in Access to Systemic Treatment for Breast Cancer in Thailand and Major Asian Territories","authors":"S. Ithimakin, N. Parinyanitikul, Sung-Bae Kim, Y. Yap, J. Tsang, I. Soong, Y. Ozaki, S. Ohno, M. Ono, Jack Junjie Chan, Hung-Chun Cheng, T. Dejthevaporn","doi":"10.4048/jbc.2022.25.e21","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e21","url":null,"abstract":"Purpose Breast cancer (BC) treatment has shifted from chemotherapy to targeted therapy. Several targeted agents have demonstrated an improvement in survival. Given that national healthcare resources were correlated with the cancer mortality-to-incidence ratio, we compared access to BC drugs in Thailand with that in other Asian countries. Methods BC experts involved in the Breast International Group (BIG)-Asia in six representative groups for countries or special administrative region (SAR) in Asia (Hong Kong SAR, Japan, Korea, Taiwan, Thailand, and Singapore) were invited to participate in the survey. The questionnaire addressed national health reimbursement schemes, molecular testing for early BC (EBC), availability and accessibility of BC drugs. Accessibility and reimbursement of the drugs were reported based on their listing as essential medicines in the World Health Organization Model List of Essential Medicines (WHO-EML) and their nomination as effective drugs in the European Society for Medical Oncology-Magnitude of Clinical Benefit Scale (ESMO-MCBS). The study was approved by all participating BIG-Asia organizations in November 2021. Results Genomic tests for EBC were non-reimbursable in all surveyed territories. Reimbursement and co-payment of BC drugs vary between and within these regions (particularly Thailand). Most drugs in the WHO-EML and ESMO-MCBS (A/B for EBC and 4/5 for advanced BC) were accessible in all surveyed territories. However, the accessibility of effective but costly WHO-EML and ESMO-MCBS drugs was not uniform in Thailand. There was an evident disparity for individuals covered by the Thai Social Security/Universal Health Coverage schemes. Conclusion Essential BC drugs are generally accessible in selected BIG-Asia countries or SAR. There is a disparity in accessing high-cost drugs in Thailand compared with other Asian territories.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"207 - 217"},"PeriodicalIF":2.4,"publicationDate":"2022-05-13","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"48048044","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice 小鼠乳腺癌诱导BALB/c小鼠慢性全身炎症和免疫抑制
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-04-26 DOI: 10.4048/jbc.2022.25.e18
D. Fuentes, A. Cabezas-Cruz, C. Mesa, T. Carmenate, Darel Martínez, Anet Valdés-Zayas, E. Montero, R. Pérez
Purpose The F3II cell line is a highly invasive variant of mammary carcinoma. Although it is frequently used as a model to evaluate the efficacy of immunotherapy, its impact on the immune system remains poorly understood. The main objectives of this study were to evaluate the effects of F3II tumors on the development of chronic inflammation and to characterize tumor-associated immunosuppression. Methods Following the experimental implantation of F3II tumors in BALB/c mice, alterations in the liver and spleen anatomy and the numbers of circulating leukocytes, myeloid-derived suppressor cells (MDSCs), and regulatory T cells were measured using hematological techniques, histopathological analysis, and flow cytometry. The capacity of the F3II tumor-bearing mice to reject MB16F10 allogeneic tumor transplantation was also evaluated. In addition, the restoration of immune parameters in tumor-bearing mice was evaluated after standard breast cancer chemotherapy and surgical tumor excision. Results F3II tumor implantation increased the levels of chronic inflammatory markers, such as the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and caused myeloid alterations, including extramedullary granulopoiesis and megakaryopoiesis, along with the recruitment of MDSCs to the spleen. Chemotherapy or surgical F3II tumor removal completely rescued the tumor-associated extramedullary granulopoiesis and megakaryopoiesis. Notably, the presence of F3II tumors reduced the capacity of BALB/c mice to reject MB16F10 allogeneic tumor transplantation. Conclusion These results support the occurrence of F3II tumor-mediated immune cell dysfunction, which mimics the immune alterations characterized by chronic systemic inflammation and immunosuppression observed in breast cancer in clinical settings. Thus, the F3II tumor model is relevant for evaluating novel breast cancer immunotherapies and combinations in preclinical studies. This model could also be useful for identifying appropriate therapeutic targets and developing proof-of-concept experiments in the future.
目的F3II细胞系是乳腺癌的一种高侵袭性变体。尽管它经常被用作评估免疫疗法疗效的模型,但对其对免疫系统的影响仍知之甚少。本研究的主要目的是评估F3II肿瘤对慢性炎症发展的影响,并表征肿瘤相关的免疫抑制。方法在BALB/c小鼠中实验性植入F3II肿瘤后,使用血液学技术、组织病理学分析和流式细胞术测量肝脏和脾脏解剖结构的变化以及循环白细胞、骨髓源性抑制细胞(MDSCs)和调节性T细胞的数量。还评估了F3II荷瘤小鼠排斥MB16F10同种异体肿瘤移植的能力。此外,在标准乳腺癌症化疗和手术切除肿瘤后,评估荷瘤小鼠免疫参数的恢复。结果F3II肿瘤植入增加了慢性炎症标志物的水平,如中性粒细胞与淋巴细胞和血小板与淋巴细胞的比例,并导致骨髓改变,包括髓外粒细胞增多和巨核细胞生成,同时MDSCs募集到脾脏。化疗或外科F3II肿瘤切除完全挽救了肿瘤相关的髓外粒细胞增多症和巨核细胞生成。值得注意的是,F3II肿瘤的存在降低了BALB/c小鼠排斥MB16F10同种异体肿瘤移植的能力。结论这些结果支持F3II肿瘤介导的免疫细胞功能障碍的发生,其模拟了临床上在癌症中观察到的以慢性全身炎症和免疫抑制为特征的免疫改变。因此,F3II肿瘤模型与临床前研究中评估新型乳腺癌症免疫疗法和组合相关。该模型还可用于确定合适的治疗靶点,并在未来开发概念验证实验。
{"title":"Murine Mammary Carcinoma Induces Chronic Systemic Inflammation and Immunosuppression in BALB/c Mice","authors":"D. Fuentes, A. Cabezas-Cruz, C. Mesa, T. Carmenate, Darel Martínez, Anet Valdés-Zayas, E. Montero, R. Pérez","doi":"10.4048/jbc.2022.25.e18","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e18","url":null,"abstract":"Purpose The F3II cell line is a highly invasive variant of mammary carcinoma. Although it is frequently used as a model to evaluate the efficacy of immunotherapy, its impact on the immune system remains poorly understood. The main objectives of this study were to evaluate the effects of F3II tumors on the development of chronic inflammation and to characterize tumor-associated immunosuppression. Methods Following the experimental implantation of F3II tumors in BALB/c mice, alterations in the liver and spleen anatomy and the numbers of circulating leukocytes, myeloid-derived suppressor cells (MDSCs), and regulatory T cells were measured using hematological techniques, histopathological analysis, and flow cytometry. The capacity of the F3II tumor-bearing mice to reject MB16F10 allogeneic tumor transplantation was also evaluated. In addition, the restoration of immune parameters in tumor-bearing mice was evaluated after standard breast cancer chemotherapy and surgical tumor excision. Results F3II tumor implantation increased the levels of chronic inflammatory markers, such as the neutrophil-to-lymphocyte and platelet-to-lymphocyte ratios, and caused myeloid alterations, including extramedullary granulopoiesis and megakaryopoiesis, along with the recruitment of MDSCs to the spleen. Chemotherapy or surgical F3II tumor removal completely rescued the tumor-associated extramedullary granulopoiesis and megakaryopoiesis. Notably, the presence of F3II tumors reduced the capacity of BALB/c mice to reject MB16F10 allogeneic tumor transplantation. Conclusion These results support the occurrence of F3II tumor-mediated immune cell dysfunction, which mimics the immune alterations characterized by chronic systemic inflammation and immunosuppression observed in breast cancer in clinical settings. Thus, the F3II tumor model is relevant for evaluating novel breast cancer immunotherapies and combinations in preclinical studies. This model could also be useful for identifying appropriate therapeutic targets and developing proof-of-concept experiments in the future.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"218 - 232"},"PeriodicalIF":2.4,"publicationDate":"2022-04-26","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"46797295","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing 靶向Kinome测序的三阴性乳腺癌突变分析
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-04-20 DOI: 10.4048/jbc.2022.25.e15
T. Yoo, W. Lee, Jisun Kim, Min Kyoon Kim, I. Park, Ju Han Kim, W. Han
Purpose Triple-negative breast cancer (TNBC) does not have defined therapeutic targets and is currently treated with chemotherapy only. Kinase dysregulation triggers cancer cell proliferation and metastasis and is a crucial therapeutic target for cancer. In this study, targeted kinome sequencing of TNBC tumors was performed to assess the association between kinome gene alterations and disease outcomes in TNBC. Methods A kinome gene panel consisting of 612 genes was used for the targeted sequencing of 166 TNBC samples and matched normal tissues. Analyses of the significantly mutated genes were performed. Genomic differences between Asian and non-Asian patients with TNBC were evaluated using two Asian TNBC datasets (from Seoul National University Hospital [SNUH] and Fudan University Shanghai Cancer Center [FUSCC]) and three non-Asian TNBC datasets (The Cancer Genome Atlas [TCGA], METABRIC, and Gustave Roussy). The prognostic value of kinome gene mutations was evaluated using tumor mutational burden (TMB) and oncogenic pathway analyses. Mutational profiles from the TCGA were used for validation. Results The significantly mutated genes included TP53 (60% of patients), PIK3CA (21%), BRCA2 (8%), and ATM (8%). Compared with data from non-Asian public databases, the mutation rates of PIK3CA p.H1047R/Q were significantly higher in the SNUH cohort (p = 0.003, 0.048, and 0.032, respectively). This was verified using the FUSCC dataset (p = 0.003, 0.078, and 0.05, respectively). The TMB-high group showed a trend toward longer progression-free survival in our cohort and the TCGA TNBC cohort (p = 0.041 and 0.195, respectively). Kinome gene alterations in the Wnt pathway in patients with TNBC were associated with poor survival in both datasets (p = 0.002 and 0.003, respectively). Conclusion Comprehensive analyses of kinome gene alterations in TNBC revealed genomic alterations that offer therapeutic targets and should help identify high-risk patients more precisely in future studies.
目的癌症三阴性(TNBC)没有明确的治疗靶点,目前仅采用化疗治疗。激酶失调触发癌症细胞增殖和转移,是癌症的重要治疗靶点。在这项研究中,对TNBC肿瘤进行了靶向kinome测序,以评估TNBC中kinome基因改变与疾病结果之间的关系。方法采用由612个基因组成的kinome基因组对166份TNBC样本和匹配的正常组织进行靶向测序。对显著突变的基因进行了分析。使用两个亚洲TNBC数据集(来自首尔国立大学医院[SNUH]和复旦大学上海癌症中心[FUSCC])和三个非亚洲TNBC资料集(癌症基因组图谱[TCGA]、METABRIC和Gustave Roussy)评估亚洲和非亚洲TNBC患者之间的基因组差异。使用肿瘤突变负荷(TMB)和致癌途径分析来评估kinome基因突变的预后价值。TCGA的突变图谱用于验证。结果TP53(60%)、PIK3CA(21%)、BRCA2(8%)和ATM(8%)基因突变显著。与非亚洲公共数据库的数据相比,SNUH队列中PIK3CA p.H1047R/Q的突变率显著较高(分别为p=0.003、0.048和0.032)。使用FUSCC数据集对此进行了验证(p分别为0.003、0.078和0.05)。TMB高组在我们的队列和TCGA TNBC队列中显示出无进展生存期更长的趋势(分别为p=0.041和0.195)。TNBC患者Wnt通路中的Kinome基因改变与两个数据集中的低生存率相关(分别为p=0.002和0.003)。结论对TNBC中kinome基因改变的综合分析揭示了基因组改变提供了治疗靶点,并有助于在未来的研究中更准确地识别高危患者。
{"title":"Mutational Analysis of Triple-Negative Breast Cancer Using Targeted Kinome Sequencing","authors":"T. Yoo, W. Lee, Jisun Kim, Min Kyoon Kim, I. Park, Ju Han Kim, W. Han","doi":"10.4048/jbc.2022.25.e15","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e15","url":null,"abstract":"Purpose Triple-negative breast cancer (TNBC) does not have defined therapeutic targets and is currently treated with chemotherapy only. Kinase dysregulation triggers cancer cell proliferation and metastasis and is a crucial therapeutic target for cancer. In this study, targeted kinome sequencing of TNBC tumors was performed to assess the association between kinome gene alterations and disease outcomes in TNBC. Methods A kinome gene panel consisting of 612 genes was used for the targeted sequencing of 166 TNBC samples and matched normal tissues. Analyses of the significantly mutated genes were performed. Genomic differences between Asian and non-Asian patients with TNBC were evaluated using two Asian TNBC datasets (from Seoul National University Hospital [SNUH] and Fudan University Shanghai Cancer Center [FUSCC]) and three non-Asian TNBC datasets (The Cancer Genome Atlas [TCGA], METABRIC, and Gustave Roussy). The prognostic value of kinome gene mutations was evaluated using tumor mutational burden (TMB) and oncogenic pathway analyses. Mutational profiles from the TCGA were used for validation. Results The significantly mutated genes included TP53 (60% of patients), PIK3CA (21%), BRCA2 (8%), and ATM (8%). Compared with data from non-Asian public databases, the mutation rates of PIK3CA p.H1047R/Q were significantly higher in the SNUH cohort (p = 0.003, 0.048, and 0.032, respectively). This was verified using the FUSCC dataset (p = 0.003, 0.078, and 0.05, respectively). The TMB-high group showed a trend toward longer progression-free survival in our cohort and the TCGA TNBC cohort (p = 0.041 and 0.195, respectively). Kinome gene alterations in the Wnt pathway in patients with TNBC were associated with poor survival in both datasets (p = 0.002 and 0.003, respectively). Conclusion Comprehensive analyses of kinome gene alterations in TNBC revealed genomic alterations that offer therapeutic targets and should help identify high-risk patients more precisely in future studies.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"164 - 177"},"PeriodicalIF":2.4,"publicationDate":"2022-04-20","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"41469908","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 1
The Predictive Value of Magnetic Resonance Imaging-based Texture Analysis in Evaluating Histopathological Grades of Breast Phyllodes Tumor. 基于磁共振成像的织构分析对乳腺叶状瘤组织病理分级的预测价值。
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-04-01 DOI: 10.4048/jbc.2022.25.e14
Yifei Mao, Zhongtang Xiong, Songxin Wu, Zhiqing Huang, Ruoxian Zhang, Yuqin He, Yuling Peng, Yang Ye, Tianfa Dong, Hui Mai

Purpose: Knowing the distinction between benign and borderline/malignant phyllodes tumors (PTs) can help in the surgical treatment course. Herein, we investigated the value of magnetic resonance imaging-based texture analysis (MRI-TA) in differentiating between benign and borderline/malignant PTs.

Methods: Forty-three women with 44 histologically proven PTs underwent breast MRI before surgery and were classified into benign (n = 26) and borderline/malignant groups (n = 18 [15 borderline, 3 malignant]). Clinical and routine MRI parameters (CRMP) and MRI-TA were used to distinguish benign from borderline/malignant PT. In total, 298 texture parameters were extracted from fat-suppression (FS) T2-weighted, FS unenhanced T1-weighted, and FS first-enhanced T1-weighted sequences. To evaluate the diagnostic performance, receiver operating characteristic curve analysis was performed for the K-nearest neighbor classifier trained with significantly different parameters of CRMP, MRI sequence-based TA, and the combination strategy.

Results: Compared with benign PTs, borderline/malignant ones presented a higher local recurrence (p = 0.045); larger size (p < 0.001); different time-intensity curve pattern (p = 0.010); and higher frequency of strong lobulation (p = 0.024), septation enhancement (p = 0.048), cystic component (p = 0.023), and irregular cystic wall (p = 0.045). TA of FS T2-weighted images (0.86) showed a significantly higher area under the curve (AUC) than that of FS unenhanced T1-weighted (0.65, p = 0.010) or first-enhanced phase (0.72, p = 0.049) images. The texture parameters of FS T2-weighted sequences tended to have a higher AUC than CRMP (0.79, p = 0.404). Additionally, the combination strategy exhibited a similar AUC (0.89, p = 0.622) in comparison with the texture parameters of FS T2-weighted sequences.

Conclusion: MRI-TA demonstrated good predictive performance for breast PT pathological grading and could provide surgical planning guidance. Clinical data and routine MRI features were also valuable for grading PTs.

目的:了解良性与交界性/恶性叶状瘤(PTs)的区别,有助于外科治疗。在此,我们研究了基于磁共振成像的纹理分析(MRI-TA)在鉴别良性和交界性/恶性PTs中的价值。方法:43例经组织学证实的44例PTs患者术前行乳腺MRI检查,分为良性组(n = 26)和交界/恶性组(n = 18[交界型15例,恶性3例])。临床和常规MRI参数(CRMP)和MRI- ta用于区分良性和交界性/恶性PT。总共从脂肪抑制(FS) t2加权、FS未增强t1加权和FS首次增强t1加权序列中提取298个纹理参数。为了评估诊断性能,对使用CRMP、基于MRI序列的TA和组合策略的显著不同参数训练的k近邻分类器进行受试者工作特征曲线分析。结果:与良性PTs相比,交界性/恶性PTs的局部复发率较高(p = 0.045);较大的尺寸(p < 0.001);不同时间-强度曲线模式(p = 0.010);分叶性强(p = 0.024)、分隔增强(p = 0.048)、囊性成分(p = 0.023)、囊壁不规则(p = 0.045)的出现频率较高。FS t2加权影像TA值(0.86)显示曲线下面积(AUC)明显高于FS未增强t1加权影像(0.65,p = 0.010)或首增强影像(0.72,p = 0.049)。FS t2加权序列的纹理参数AUC高于CRMP序列(0.79,p = 0.404)。此外,组合策略与FS t2加权序列的纹理参数具有相似的AUC (0.89, p = 0.622)。结论:MRI-TA对乳腺PT病理分级具有较好的预测效果,可为手术规划提供指导。临床资料和常规MRI特征对PTs分级也有价值。
{"title":"The Predictive Value of Magnetic Resonance Imaging-based Texture Analysis in Evaluating Histopathological Grades of Breast Phyllodes Tumor.","authors":"Yifei Mao,&nbsp;Zhongtang Xiong,&nbsp;Songxin Wu,&nbsp;Zhiqing Huang,&nbsp;Ruoxian Zhang,&nbsp;Yuqin He,&nbsp;Yuling Peng,&nbsp;Yang Ye,&nbsp;Tianfa Dong,&nbsp;Hui Mai","doi":"10.4048/jbc.2022.25.e14","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e14","url":null,"abstract":"<p><strong>Purpose: </strong>Knowing the distinction between benign and borderline/malignant phyllodes tumors (PTs) can help in the surgical treatment course. Herein, we investigated the value of magnetic resonance imaging-based texture analysis (MRI-TA) in differentiating between benign and borderline/malignant PTs.</p><p><strong>Methods: </strong>Forty-three women with 44 histologically proven PTs underwent breast MRI before surgery and were classified into benign (n = 26) and borderline/malignant groups (n = 18 [15 borderline, 3 malignant]). Clinical and routine MRI parameters (CRMP) and MRI-TA were used to distinguish benign from borderline/malignant PT. In total, 298 texture parameters were extracted from fat-suppression (FS) T2-weighted, FS unenhanced T1-weighted, and FS first-enhanced T1-weighted sequences. To evaluate the diagnostic performance, receiver operating characteristic curve analysis was performed for the K-nearest neighbor classifier trained with significantly different parameters of CRMP, MRI sequence-based TA, and the combination strategy.</p><p><strong>Results: </strong>Compared with benign PTs, borderline/malignant ones presented a higher local recurrence (<i>p</i> = 0.045); larger size (<i>p</i> < 0.001); different time-intensity curve pattern (<i>p</i> = 0.010); and higher frequency of strong lobulation (<i>p</i> = 0.024), septation enhancement (<i>p</i> = 0.048), cystic component (<i>p</i> = 0.023), and irregular cystic wall (<i>p</i> = 0.045). TA of FS T2-weighted images (0.86) showed a significantly higher area under the curve (AUC) than that of FS unenhanced T1-weighted (0.65, <i>p</i> = 0.010) or first-enhanced phase (0.72, <i>p</i> = 0.049) images. The texture parameters of FS T2-weighted sequences tended to have a higher AUC than CRMP (0.79, <i>p</i> = 0.404). Additionally, the combination strategy exhibited a similar AUC (0.89, <i>p</i> = 0.622) in comparison with the texture parameters of FS T2-weighted sequences.</p><p><strong>Conclusion: </strong>MRI-TA demonstrated good predictive performance for breast PT pathological grading and could provide surgical planning guidance. Clinical data and routine MRI features were also valuable for grading PTs.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 2","pages":"117-130"},"PeriodicalIF":2.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://ftp.ncbi.nlm.nih.gov/pub/pmc/oa_pdf/91/7e/jbc-25-117.PMC9065359.pdf","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"10303488","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 2
Corrigendum: Artificial Intelligence for Breast Cancer Screening in Mammography (AI-STREAM): A Prospective Multicenter Study Design in Korea Using AI-Based CADe/x 更正:乳腺造影术中癌症筛查的人工智能(AI-STREAM):韩国使用基于AI的CADe/x的前瞻性多中心研究设计
IF 2.4 4区 医学 Q3 ONCOLOGY Pub Date : 2022-04-01 DOI: 10.4048/jbc.2022.25.e16
Y. Chang, J. An, N. Choi, Kyung Hee Ko, Ki Hwan Kim, Kyunghwa Han, J. Ryu
This corrects the article on p. 57 in vol. 25, PMID: 35133093.
这更正了第25卷第57页的文章,PMID:35133093。
{"title":"Corrigendum: Artificial Intelligence for Breast Cancer Screening in Mammography (AI-STREAM): A Prospective Multicenter Study Design in Korea Using AI-Based CADe/x","authors":"Y. Chang, J. An, N. Choi, Kyung Hee Ko, Ki Hwan Kim, Kyunghwa Han, J. Ryu","doi":"10.4048/jbc.2022.25.e16","DOIUrl":"https://doi.org/10.4048/jbc.2022.25.e16","url":null,"abstract":"This corrects the article on p. 57 in vol. 25, PMID: 35133093.","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"147 - 147"},"PeriodicalIF":2.4,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"49521813","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
Ipsilateral Lymphadenopathy After COVID-19 Vaccination in Patients With Newly Diagnosed Breast Cancer. 新诊断癌症患者接种新冠肺炎疫苗后的同侧淋巴结病
IF 2.2 4区 医学 Q3 ONCOLOGY Pub Date : 2022-04-01 Epub Date: 2021-03-03 DOI: 10.4048/jbc.2022.25.e10
Su Min Ha, Jong-Ho Cheun, Su Hyun Lee, Soo-Yeon Kim, Ah Reum Park, Yeon Soo Kim, Heera Yoen, Youkyoung Lee, Nariya Cho, Woo Kyung Moon, Jung Min Chang

This study aimed to evaluate the imaging and pathological findings in axillary lymph nodes in patients with breast cancer who received concurrent ipsilateral coronavirus disease 2019 (COVID-19) vaccination. Of the 19 women with breast cancer who received concurrent COVID-19 vaccination shot in the arm ipsilateral to breast cancer, axillary lymphadenopathy was observed in 84.2% (16 of 19) of patients on ultrasound (US) and 71.4% (10 of 14) of patients on magnetic resonance imaging (MRI), and 21.0% (4 of 19) of patients were diagnosed with metastasis. Abnormal US and MRI findings of cortical thickening, effacement of the fatty hilum, round shape, and asymmetry in the number or size relative to the contralateral side were noted in more than half of the non-metastatic and metastatic lymph nodes; however, statistical significance was not noted. Axillary lymphadenopathy is commonly observed in patients with breast cancer who receive concurrent ipsilateral COVID-19 vaccination without specific differential imaging features. Thus, understanding the limitations of axillary imaging and cautious interpretation is necessary to avoid overestimation or underestimation of the axillary disease burden.

本研究旨在评估同时接种2019年同侧冠状病毒病(新冠肺炎)疫苗的癌症患者腋窝淋巴结的影像学和病理学结果。在19名同时在癌症同侧手臂接种新冠肺炎疫苗的癌症女性中,84.2%(19例中的16例)的超声(US)患者和71.4%(14例中的10例)的磁共振成像(MRI)患者观察到腋窝淋巴结病,21.0%(4例中的19例)的患者被诊断为转移。超过一半的非转移性和转移性淋巴结出现皮质增厚、脂肪门消失、圆形以及相对于对侧数量或大小不对称的异常US和MRI表现;然而,没有注意到统计学上的显著性。在癌症同时接受同侧新冠肺炎疫苗接种的患者中,通常观察到腋窝淋巴结病,但没有特定的不同影像学特征。因此,了解腋窝成像的局限性和谨慎的解释是必要的,以避免高估或低估腋窝疾病负担。
{"title":"Ipsilateral Lymphadenopathy After COVID-19 Vaccination in Patients With Newly Diagnosed Breast Cancer.","authors":"Su Min Ha, Jong-Ho Cheun, Su Hyun Lee, Soo-Yeon Kim, Ah Reum Park, Yeon Soo Kim, Heera Yoen, Youkyoung Lee, Nariya Cho, Woo Kyung Moon, Jung Min Chang","doi":"10.4048/jbc.2022.25.e10","DOIUrl":"10.4048/jbc.2022.25.e10","url":null,"abstract":"<p><p>This study aimed to evaluate the imaging and pathological findings in axillary lymph nodes in patients with breast cancer who received concurrent ipsilateral coronavirus disease 2019 (COVID-19) vaccination. Of the 19 women with breast cancer who received concurrent COVID-19 vaccination shot in the arm ipsilateral to breast cancer, axillary lymphadenopathy was observed in 84.2% (16 of 19) of patients on ultrasound (US) and 71.4% (10 of 14) of patients on magnetic resonance imaging (MRI), and 21.0% (4 of 19) of patients were diagnosed with metastasis. Abnormal US and MRI findings of cortical thickening, effacement of the fatty hilum, round shape, and asymmetry in the number or size relative to the contralateral side were noted in more than half of the non-metastatic and metastatic lymph nodes; however, statistical significance was not noted. Axillary lymphadenopathy is commonly observed in patients with breast cancer who receive concurrent ipsilateral COVID-19 vaccination without specific differential imaging features. Thus, understanding the limitations of axillary imaging and cautious interpretation is necessary to avoid overestimation or underestimation of the axillary disease burden.</p>","PeriodicalId":15206,"journal":{"name":"Journal of Breast Cancer","volume":"25 1","pages":"131-139"},"PeriodicalIF":2.2,"publicationDate":"2022-04-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9065357/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"45533432","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
引用次数: 0
期刊
Journal of Breast Cancer
全部 Acc. Chem. Res. ACS Applied Bio Materials ACS Appl. Electron. Mater. ACS Appl. Energy Mater. ACS Appl. Mater. Interfaces ACS Appl. Nano Mater. ACS Appl. Polym. Mater. ACS BIOMATER-SCI ENG ACS Catal. ACS Cent. Sci. ACS Chem. Biol. ACS Chemical Health & Safety ACS Chem. Neurosci. ACS Comb. Sci. ACS Earth Space Chem. ACS Energy Lett. ACS Infect. Dis. ACS Macro Lett. ACS Mater. Lett. ACS Med. Chem. Lett. ACS Nano ACS Omega ACS Photonics ACS Sens. ACS Sustainable Chem. Eng. ACS Synth. Biol. Anal. Chem. BIOCHEMISTRY-US Bioconjugate Chem. BIOMACROMOLECULES Chem. Res. Toxicol. Chem. Rev. Chem. Mater. CRYST GROWTH DES ENERG FUEL Environ. Sci. Technol. Environ. Sci. Technol. Lett. Eur. J. Inorg. Chem. IND ENG CHEM RES Inorg. Chem. J. Agric. Food. Chem. J. Chem. Eng. Data J. Chem. Educ. J. Chem. Inf. Model. J. Chem. Theory Comput. J. Med. Chem. J. Nat. Prod. J PROTEOME RES J. Am. Chem. Soc. LANGMUIR MACROMOLECULES Mol. Pharmaceutics Nano Lett. Org. Lett. ORG PROCESS RES DEV ORGANOMETALLICS J. Org. Chem. J. Phys. Chem. J. Phys. Chem. A J. Phys. Chem. B J. Phys. Chem. C J. Phys. Chem. Lett. Analyst Anal. Methods Biomater. Sci. Catal. Sci. Technol. Chem. Commun. Chem. Soc. Rev. CHEM EDUC RES PRACT CRYSTENGCOMM Dalton Trans. Energy Environ. Sci. ENVIRON SCI-NANO ENVIRON SCI-PROC IMP ENVIRON SCI-WAT RES Faraday Discuss. Food Funct. Green Chem. Inorg. Chem. Front. Integr. Biol. J. Anal. At. Spectrom. J. Mater. Chem. A J. Mater. Chem. B J. Mater. Chem. C Lab Chip Mater. Chem. Front. Mater. Horiz. MEDCHEMCOMM Metallomics Mol. Biosyst. Mol. Syst. Des. Eng. Nanoscale Nanoscale Horiz. Nat. Prod. Rep. New J. Chem. Org. Biomol. Chem. Org. Chem. Front. PHOTOCH PHOTOBIO SCI PCCP Polym. Chem.
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
0
微信
客服QQ
Book学术公众号 扫码关注我们
反馈
×
意见反馈
请填写您的意见或建议
请填写您的手机或邮箱
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
现在去查看 取消
×
提示
确定
Book学术官方微信
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术
文献互助 智能选刊 最新文献 互助须知 联系我们:info@booksci.cn
Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。
Copyright © 2023 Book学术 All rights reserved.
ghs 京公网安备 11010802042870号 京ICP备2023020795号-1